Musa Mayer

7.7k total citations · 1 hit paper
55 papers, 1.9k citations indexed

About

Musa Mayer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Musa Mayer has authored 55 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 21 papers in Cancer Research. Recurrent topics in Musa Mayer's work include Cancer Treatment and Pharmacology (21 papers), Breast Cancer Treatment Studies (17 papers) and HER2/EGFR in Cancer Research (16 papers). Musa Mayer is often cited by papers focused on Cancer Treatment and Pharmacology (21 papers), Breast Cancer Treatment Studies (17 papers) and HER2/EGFR in Cancer Research (16 papers). Musa Mayer collaborates with scholars based in United States, United Kingdom and Germany. Musa Mayer's co-authors include Ruth Etzioni, Angela B. Mariotto, Lynne Penberthy, Marc Hurlbert, Peter A. Kaufman, Denise A. Yardley, Hope S. Rugo, Adam Brufsky, Marianne Ulcickas Yood and Debu Tripathy and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Cancer.

In The Last Decade

Musa Mayer

52 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States

2017 381 citations Angela B. Mariotto, Ruth Etzioni et al. Cancer Epidemiology Biomarkers & Prevention profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Musa Mayer United States	17	1.3k	760	562	328	195	55	1.9k
Mohammad Jahanzeb United States	17	960 0.7×	547 0.7×	390 0.7×	356 1.1×	198 1.0×	32	1.5k
Harpreet Singh United States	24	1.0k 0.8×	647 0.9×	427 0.8×	495 1.5×	128 0.7×	101	1.8k
Alessandro Marco Minisini Italy	24	1.1k 0.9×	603 0.8×	589 1.0×	425 1.3×	147 0.8×	76	1.9k
Vernon Harvey New Zealand	22	1.3k 1.0×	357 0.5×	489 0.9×	258 0.8×	312 1.6×	44	1.8k
Felix E. de Jongh Netherlands	22	1.2k 1.0×	448 0.6×	385 0.7×	250 0.8×	334 1.7×	34	2.1k
Mayu Yunokawa Japan	25	1.1k 0.9×	482 0.6×	373 0.7×	511 1.6×	312 1.6×	140	2.1k
Hervé Curé France	20	1.3k 1.0×	827 1.1×	510 0.9×	279 0.9×	297 1.5×	52	2.3k
Konstantinos Tryfonidis Belgium	20	1.1k 0.9×	406 0.5×	771 1.4×	326 1.0×	146 0.7×	53	1.7k
Chris Twelves United Kingdom	20	1.3k 1.0×	507 0.7×	399 0.7×	219 0.7×	56 0.3×	44	1.8k
Jacob J. Adashek United States	24	816 0.6×	506 0.7×	416 0.7×	338 1.0×	107 0.5×	106	1.5k

Countries citing papers authored by Musa Mayer

Since Specialization

Citations

This map shows the geographic impact of Musa Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Musa Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Musa Mayer more than expected).

Fields of papers citing papers by Musa Mayer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Musa Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Musa Mayer. The network helps show where Musa Mayer may publish in the future.

Co-authorship network of co-authors of Musa Mayer

This figure shows the co-authorship network connecting the top 25 collaborators of Musa Mayer. A scholar is included among the top collaborators of Musa Mayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Musa Mayer. Musa Mayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mariotto, Angela B., Ruth Etzioni, Marc Hurlbert, Lynne Penberthy, & Musa Mayer. (2017). Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. Cancer Epidemiology Biomarkers & Prevention. 26(6). 809–815. 381 indexed citations breakdown →

Malmgren, Judith A., Musa Mayer, Mary Atwood, & Henry G. Kaplan. (2017). Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Research and Treatment. 167(2). 579–590. 99 indexed citations

Yardley, Denise A., Ian E. Krop, Patricia LoRusso, et al.. (2015). Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents. The Cancer Journal. 21(5). 357–364. 27 indexed citations

Kaufman, Peter A., Kenneth J. Bloom, Howard A. Burris, et al.. (2014). Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Cancer. 120(17). 2657–2664. 47 indexed citations

Cleeland, Charles S., Musa Mayer, Nancy A Dreyer, et al.. (2014). Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study. The Breast. 23(6). 763–769. 53 indexed citations

Yardley, Denise A., Peter A. Kaufman, Adam Brufsky, et al.. (2014). Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 145(3). 725–734. 61 indexed citations

Yardley, Denise A., Debu Tripathy, Adam Brufsky, et al.. (2014). Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. British Journal of Cancer. 110(11). 2756–2764. 51 indexed citations

Marino, Natascia, Stephan Woditschka, L. Tiffany Reed, et al.. (2013). Breast Cancer Metastasis. American Journal Of Pathology. 183(4). 1084–1095. 249 indexed citations

Rugo, Hope S., Adam Brufsky, Marianne Ulcickas Yood, et al.. (2013). Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 141(3). 461–470. 39 indexed citations

10.

Kaufman, Peter A., Adam Brufsky, Musa Mayer, et al.. (2012). Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Research and Treatment. 135(3). 875–883. 45 indexed citations

11.

Brufsky, Adam, Musa Mayer, Hope S. Rugo, et al.. (2011). Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER. Clinical Cancer Research. 17(14). 4834–4843. 283 indexed citations

12.

Mayer, Musa. (2011). Living with advanced breast cancer: Challenges and opportunities. The Breast. 20. S12–S13. 5 indexed citations

13.

Mayer, Musa. (2010). Lessons Learned From the Metastatic Breast Cancer Community. Seminars in Oncology Nursing. 26(3). 195–202. 36 indexed citations

14.

Mayer, Musa. (2008). Swimming Upstream: An Advocate Reflects on Cancer Research and Social Realities. Journal of Clinical Oncology. 26(16). 2783–2786. 3 indexed citations

15.

Yardley, Denise A., Peter A. Kaufman, Musa Mayer, et al.. (2007). registHER: Patient characteristics, treatment patterns, and preliminary outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 25(18_suppl). 21007–21007. 1 indexed citations

16.

Dickersin, Kay, Pamela Klein, Musa Mayer, et al.. (2007). Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nature reviews. Cancer. 7(4). 309–315. 70 indexed citations

17.

Mayer, Musa. (2005). When Clinical Trials Are Compromised: A Perspective from a Patient Advocate. PLoS Medicine. 2(11). e358–e358. 2 indexed citations

18.

Mayer, Musa. (2003). From Access to Evidence: An Advocate’s Journey. Journal of Clinical Oncology. 21(20). 3881–3884. 8 indexed citations

19.

Mayer, Musa, et al.. (1988). Bile levels of imipenem in patients with t-drain following the administration of Imipenem/Cilastatin. Infection. 16(4). 225–228. 8 indexed citations

20.

Saez, S & Musa Mayer. (1977). Facteurs hormonaux de prévision d'hormonodépendance du cancer du sein.. Bulletin du Cancer. 64(4). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact